The RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infection-study protocol for a two-stage randomised phase II trial

Autor: Ming Jie Lee, Simon Collins, Daphne Babalis, Nicholas Johnson, Emanuela Falaschetti, A. Toby Prevost, Ambreen Ashraf, Milaana Jacob, Tom Cole, Lisa Hurley, Matthew Pace, Ane Ogbe, Maryam Khan, Panagiota Zacharopoulou, Helen Brown, Euan Sutherland, Hanna Box, Julie Fox, Steven Deeks, Jill Horowitz, Michel C. Nussenzweig, Marina Caskey, John Frater, Sarah Fidler

Publikováno v: Lee, M J, Collins, S, Babalis, D, Johnson, N, Falaschetti, E, Prevost, A T, Ashraf, A, Jacob, M, Cole, T, Hurley, L, Pace, M, Ogbe, A, Khan, M, Zacharopoulou, P, Brown, H, Sutherland, E, Box, H, Fox, J, Deeks, S, Horowitz, J, Nussenzweig, M C, Caskey, M, Frater, J & Fidler, S 2022, ' The RIO trial : rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infection—study protocol for a two-stage randomised phase II trial ', Trials, vol. 23, no. 1, 263 . https://doi.org/10.1186/s13063-022-06151-w

Background Antiretroviral therapy (ART) has led to dramatic improvements in survival for people living with HIV, but is unable to cure infection, or induce viral control off therapy. Designing intervention trials with novel agents with the potential

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5ad9dd85694593e13ab4d4bb20f4adf
https://pubmed.ncbi.nlm.nih.gov/35382844